Clinical trial
Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
NCT00407355 · Peter A Campochiaro, MD, Other · Completed
Key facts
| NCT number | NCT00407355 |
|---|---|
| Title | Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions |
| Official title | A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects With Macular Edema Secondary to Vein Occlusions. |
| Acronym | LVO |
| Lead sponsor | Peter A Campochiaro, MD, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Macular Edema, Retinal Vein Occlusion |
| Intervention type | Drug |
| Interventions | Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose |
| Enrollment | 40 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2013 |
| Completion | Feb 1, 2013 |
| First posted | Dec 5, 2006 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: